INSMED INC
NASDAQ: INSM (Insmed Incorporated)
Last update: 2 hours ago108.76
-1.24 (-1.13%)
| Previous Close | 110.00 |
| Volume | 2,616,032 |
| Price / Earnings (Forward) | 71.43 |
| Price / Sales | 15.66 |
| Price / Book | 33.22 |
| 52 Weeks Range |
| Profit Margin | -265.93% |
| Operating Margin (TTM) | -247.61% |
| Diluted EPS (TTM) | -5.93 |
| Quarterly Revenue Growth (YOY) | 22.90% |
| Total Debt/Equity (MRQ) | 1,316.96% |
| Current Ratio (MRQ) | 5.86 |
| Operating Cash Flow (TTM) | -761.93 M |
| Levered Free Cash Flow (TTM) | -480.63 M |
| Return on Assets (TTM) | -36.25% |
| Return on Equity (TTM) | -890.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Insmed Incorporated | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.2 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.21 |
Select this tab to load the latest available analysis.
|
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 110.72% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jpmorgan Chase & Co | 30 Jun 2026 | 10,428,170 |
| Baker Bros. Advisors Lp | 30 Jun 2026 | 8,796,111 |
| Capital International Investors | 30 Jun 2026 | 8,238,124 |
| Darwin Global Management, Ltd. | 30 Jun 2026 | 6,431,163 |
| Orbis Allan Gray Ltd | 30 Jun 2026 | 6,076,487 |
| Artisan Partners Limited Partnership | 30 Jun 2026 | 5,441,718 |
| Rtw Investments, Lp | 30 Jun 2026 | 4,842,880 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |